<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786058</url>
  </required_header>
  <id_info>
    <org_study_id>CONKO 003</org_study_id>
    <secondary_id>CCT-NAPN-16751</secondary_id>
    <nct_id>NCT00786058</nct_id>
  </id_info>
  <brief_title>A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003</brief_title>
  <official_title>A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CONKO-Studiengruppe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CONKO-Studiengruppe</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/&#xD;
      5-FU versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine (G) given until progressive disease (PD) is still standard therapy in patients&#xD;
      with advanced pancreatic cancer. No standard secondline regimen is available after PD. Best&#xD;
      supportive care (BSC) is the main option for these patients. Our phase II study (Pelzer et&#xD;
      al, ASCO 2002) showed activity of the OFF (Oxaliplatin/Folinic Acid/5-FU) regimen. To confirm&#xD;
      these data we started this multicenter phase III study to examine OFF vs. BSC alone.&#xD;
&#xD;
      165 patients were needed for this study. Following CT/ MRT confirmed PD patients were&#xD;
      randomized. Stratification included duration of firstline therapy, Karnofsky Performance&#xD;
      Status (KPS) and tumor stage. OFF (outpatient regimen): 5-FU 2g/m² (24h)/FA 200 mg/m² (30min)&#xD;
      on d1, d8, d15, d22, additional Oxaliplatin 85mg/m² (2h) on day 8 and 22. Rest on day 23 and&#xD;
      42.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFF in experimental arm</intervention_name>
    <description>OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.</description>
    <other_name>Eloxatin</other_name>
    <other_name>Calciumfolinat</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed metastatic pancreatic&#xD;
             adenocarcinoma that had progressed during first line gemcitabine therapy were eligible&#xD;
             for inclusion in the study.&#xD;
&#xD;
        Other inclusion criteria were:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70%&#xD;
&#xD;
          -  Bidimensionally measurable reference lesion, adequate laboratory values for hematology&#xD;
             (white blood cell [WBC] count &gt; 3.5´109/L, platelet count &gt; 100´109/L), renal function&#xD;
             (creatine clearance &gt; 30 ml/min) and hepatic function (aspartate aminotransferase&#xD;
             [AST] or alanine aminotransferase [ALT] &lt; 2.5 ´ upper normal limit [UNL] and in the&#xD;
             case of liver metastasis &lt; 5 x UNL)&#xD;
&#xD;
          -  As well as controlled pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients were excluded from the study if they had any severe concurrent medical&#xD;
             condition interfering with planned therapy, serious cardiac disease, sensory/ motor&#xD;
             neuropathy &gt; grade 2 or had previous or current malignancies at other origin; besides,&#xD;
             pregnant or lactating women were excluded.&#xD;
&#xD;
          -  All patients provided written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Helmut Oettle, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CONKO Study Group</affiliation>
  </overall_official>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>June 12, 2009</last_update_submitted>
  <last_update_submitted_qc>June 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Helmut Oettle PHD</name_title>
    <organization>CONKO Study group</organization>
  </responsible_party>
  <keyword>refractory pancreatic cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>phase III</keyword>
  <keyword>second line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

